

**REMARKS**

**STATUS OF THE CLAIMS:**

Claims 1 to 40, 48 and 49, 51, 58 to 63, and 66 are cancelled.

Claim 41 was amended.

Claims 41 to 47, 50, 52 to 57, 64 and 65, and 67 to 72 are pending.


Claim 41 was amended to substitute the phrase “corresponding to” with the phrase “comprising” in sub-clauses (a), (b), and (c); to delete the phrase “ including the start codon” in sub-clause (a); and to delete the phrase “ minus the start codon” in sub-clause (b); in order to place this claim in better condition for issuance. Applicants reserve the right to prosecute Claim 41 as originally presented in related applications. Applicants right to equivalents of Claim 41 is reserved. No new matter has been added.

If any small matter should remain outstanding after the Patent Examiner has had an opportunity to review the above Remarks, the Patent Examiner is respectfully requested to telephone the undersigned attorney in order to resolve these matters.

Although it is believed no fee is due, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment associated with the filing of this correspondence to Deposit Account Number 19-3880 in the name of the Bristol-Myers Squibb Company.

Respectfully submitted,

Bristol-Myers Squibb Company  
Patent Department  
P.O. Box 4000  
Princeton, NJ 08543-4000  
609-252-3575

  
Stephen C. D'Amico  
Agent for Applicants  
Reg. No. 46,652

Date: April 1, 2005